VEGF-F / svVEGF antibody

Principal name

VEGF-F / svVEGF antibody

Alternative names for VEGF-F / svVEGF antibody

Snake venom vascular endothelial growth factor toxin

SwissProt ID

Q90X24 (Botin)

Ncbi ID

8723

Available reactivities

Snake

Available hosts

Rabbit

Available applications

Western blot / Immunoblot (WB)

Background of VEGF-F / svVEGF antibody

Vascular endothelial growth factor (VEGF-A) and its family proteins are crucial regulators of blood vessel formation and vascular permeability. Snake venom has recently been shown to be an exogenous source of unique VEGF (known as VEGF-F), and now, two types of VEGF-F with distinct biochemical properties have been reported. VEGF-Fs (venom type VEGFs) are highly variable in structure and function among species, in contrast to endogenous tissue-type VEGFs (VEGF-As) of snakes. Although the structures of tissue-type VEGFs are highly conserved among venomous snake species and even among all vertebrates, including humans, those of venom-type VEGFs are extensively variegated, especially in the regions around receptor-binding loops and C-terminal putative coreceptor-binding regions, indicating that highly frequent variations are located around functionally key regions of the proteins. Genetic analyses suggest that venom-type VEGF gene may have developed from a tissue-type gene and that the unique sequence of its C-terminal region was generated by an alteration in the translation frame in the corresponding exons.
The svVEGF-F was identified during the generation of abundant expressed sequence tags from the Viperidae snake Bothrops insularis venom glands. The deduced primary sequence, after complete sequencing of the longest snake venom VEGF (svVEGF) cDNA, displayed similarity with vertebrate VEGFs and with the hypotensive factor from Vipera aspis venom. The mature svVEGF appears to be ubiquitously distributed throughout snake venoms and was also confirmed by Northern blot studies of other related Viperidae species and by cDNA cloning of svVEGF from Bothrops jararaca pit viper. The produced recombinant protein dimerizes after refolding processes and was biologically characterized, showing ability to increase vascular permeability. These results established that svVEGF is a novel and important active toxin during the early stages of bothropic snake bite envenoming and represents a new member of the VEGF family of proteins.

5 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

VEGF-F / svVEGF antibody

Western Blot Analysis using a Protein-A purified antibody against svVEGF-F (Bothrops Insularis). Recombinant svVEGF-F produced in E. coli was used for immunization. The antibody detects the monomeric svVEGF-F but shows no cross reactivity with related proteins like mouse und human VEGF-A, VEGF-C and PlGF. A weaker band is visible at about 26 kDa which correspond to the dimeric svVEGF-F. Rabbit IgG Purified Snake WB
0.2 mg / €370.00
  Acris Antibodies GmbH

VEGF-F / svVEGF antibody

Western Blot Analysis using a Protein-A purified antibody against svVEGF-F (Bothrops Insularis). Recombinant svVEGF-F produced in E. coli was used for immunization. The antibody detects the monomeric svVEGF-F but shows no cross reactivity with related proteins like mouse und human VEGF-A, VEGF-C and PlGF. A weaker band is visible at about 26 kDa which correspond to the dimeric svVEGF-F. Rabbit IgG Purified Snake WB
0.1 mg / €270.00
  Acris Antibodies GmbH

Proteins & Growth Factors

Catalog No. Species Pres. Purity Source  

VEGF-F / svVEGF

Proliferation assay with primary HUVECs. Human VEGF165 was used as positive control. Although svVEGF-F (20ng/ml) had a significant lower activity as Human VEGF165 (5ng/ml) it clearly induced the proliferation of HUVECs. Purified > 95 % E. coli
20 µg / €510.00
  Acris Antibodies GmbH

VEGF-F / svVEGF

Proliferation assay with primary HUVECs. Human VEGF165 was used as positive control. Although svVEGF-F (20ng/ml) had a significant lower activity as Human VEGF165 (5ng/ml) it clearly induced the proliferation of HUVECs. Purified > 95 % E. coli
5 µg / €250.00
  Acris Antibodies GmbH

VEGF-F / svVEGF

Proliferation assay with primary HUVECs. Human VEGF165 was used as positive control. Although svVEGF-F (20ng/ml) had a significant lower activity as Human VEGF165 (5ng/ml) it clearly induced the proliferation of HUVECs. Purified > 95 % E. coli
2 µg / €180.00
  Acris Antibodies GmbH

5 Item(s)

per page
  • LinkedIn